Silver Book Fact

Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.

Black, Dennis M. Desmond E. Thompson, Douglas C. Bauer, Kris Ensrud, Thomas Musliner, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, and Steven R. Cummings; for the FIT Research Group. Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial. J Clin Endocrinol Metabo. 2000; 85(11): 4118-24. http://jcem.endojournals.org/cgi/content/full/85/11/4118

Reference

Title
Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The fracture intervention trial
Publication
J Clin Endocrinol Metabo
Publication Date
2000
Authors
Black, Dennis M. Desmond E. Thompson, Douglas C. Bauer, Kris Ensrud, Thomas Musliner, Marc C. Hochberg, Michael C. Nevitt, Shailaja Suryawanshi, and Steven R. Cummings; for the FIT Research Group
Volume & Issue
Volume 85, Issue 11
Pages
4118-24
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Teriparatide, or human recombinant PTH, has been shown to increase vertebral bone mineral density (BMD) by 9% to 13%.  
  • A meta-analysis of clinical trials found that Vitamin D supplements reduced the risk of vertebral fractures by around 37%.  
  • Raloxifene, a selective estrogen receptor modulator (SERM), has been shown to decrease vertebral fractures by up to 50% after 3 years.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.